Champions Oncology Inc. (CSBR)
CSBR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-04-30, https://www.sec.gov/Archives/edgar/data/771856/000162828026049834/0001628280-26-049834-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-04-30.
Profile
| Field | Value |
|---|---|
| Ticker | CSBR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000771856 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $59.4M |
| Net income | -$1.2M |
| Operating income | -$1.1M |
| Net margin | -2.0% |
| Operating margin | -1.9% |
| Revenue growth | +4.4% |
| Cash | $4.9M |
| Total assets | $27.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-09-11 |
| Cash and burn | $4.4M cash; operating cash flow -$1.4M a quarter. | Report 2026-07-31 |
| Shares outstanding | 13,918,569 (2026-09-09); 13,788,421 a year earlier; 13,479,215 three years earlier. | Cover page 2026-09-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EisnerAmper LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-07-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-07-31 | $15.2M | -$426K | -$492K | $4.4M | No debt tags | $60.7M | 10-Q 2026-09-11 |
| Q4 2026 2026-04-30 | $13.8M | -$667K | -$2.0M | $4.9M | No debt tags | $59.4M | 10-K 2026-07-27 |
| Q3 2026 2026-01-31 | $16.6M | -$279K | -$1.3M | $7.1M | No debt tags | $57.9M | 10-Q 2026-03-12 |
| Q2 2026 2025-10-31 | $15.0M | $268K | -$1.7M | $8.5M | No debt tags | $58.4M | 10-Q 2025-12-15 |
| Q1 2026 2025-07-31 | $14.0M | -$466K | $600K | $10.3M | No debt tags | $56.9M | 10-Q 2026-09-11 |
| Q4 2025 2025-04-30 | $12.4M | -$1.8M | $6.9M | $9.8M | No debt tags | $56.9M | 10-K 2026-07-27 |
| Q3 2025 2025-01-31 | $17.0M | $4.5M | $490K | $3.2M | No debt tags | $58.6M | 10-Q 2026-03-12 |
| Q2 2025 2024-10-31 | $13.5M | $728K | -$283K | $2.8M | No debt tags | $53.6M | 10-Q 2025-12-15 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2016-06-10 |
| Latest annual report | 10-K | 2026-07-27 |
| Latest quarterly / interim | 10-Q | 2026-09-11 |
| Latest current report | 8-K | 2026-10-16 |
| Latest proxy | DEFA14A | 2026-08-28 |
Source: SEC EDGAR submissions feed, 659 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.7% |
| 1 month | -3.9% |
| 3 months | -7.3% |
| Year to date | -31.8% |
| 1 year | -31.7% |
| From 52-week high | -39.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics Inc. | $6.40 | -16.88% | $65.2M |
| CRDF | Cardiff Oncology Inc. | $0.8477 | +16.75% | $65.9M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
| NMRA | Neumora Therapeutics Inc. | $0.3695 | -13.85% | $69.4M |
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
| PMCB | PharmaCyte Biotech Inc. | $5.57 | -16.62% | $59.8M |
| AVXL | Anavex Life Sciences Corp. | $0.8176 | -12.42% | $75.8M |
| TNYA | Tenaya Therapeutics Inc. | $0.3336 | -4.47% | $76.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier